Oviva
Swiss healthtech founded in 2014 providing digital therapies for obesity, diabetes and hypertension through the NHS and European healthcare systems. Has treated over 1 million patients.
Europe's most interesting startup stories. Every week.
No spam. Unsubscribe anytime.
About Oviva
Oviva was founded in 2014 in Zurich by Kai Eberhardt and Manuel Baumann with a simple but hard-to-execute idea: making dietary and lifestyle care accessible to patients with metabolic conditions through an app — with public reimbursement. The startup built an entirely B2G (Business-to-Government) model: its digital therapies are delivered through the UK NHS, the German healthcare system and other European systems. This differentiates it radically from B2C healthtech companies dependent on direct acquisition. In January 2026, Oviva raised €200M in a Series D round to expand its AI-powered care to hypertension and type 2 diabetes, targeting total coverage across 10+ European markets. Total patients treated exceeds 1 million.
The Story
Founded in 2014 in Zurich on the thesis that certified dietary care could be delivered digitally with reimbursement from national healthcare systems.
How Oviva works
Business Model
B2G (Business-to-Government): digital therapies reimbursed by the UK NHS and European healthcare systems. Patients pay nothing directly.
Market & Clients
Geographic Presence
Funding & Investors
Funding Rounds
- 2026 - Growth: €200M
Key Investors
Founding Team
Founders
Key Metrics
Similar Startups
Ternary Therapeutics
Biotech company using synthetic biology to develop therapies for serious diseases with innovative treatment approaches.
Read AnalysisOxford Medical Simulation
Medtech company creating VR and AR simulations for medical training, surgery planning, and patient education.
Read AnalysisBioniq
Biotech platform using AI and synthetic biology to accelerate drug discovery and development timelines.
Read AnalysisSources
- Oviva — €200M Growth 2026 — Tech.eu